Lynne Wagenknecht to Apolipoproteins
This is a "connection" page, showing publications Lynne Wagenknecht has written about Apolipoproteins.
Connection Strength
0.249
-
Freedman BI, Langefeld CD, Lu L, Palmer ND, Smith SC, Bagwell BM, Hicks PJ, Xu J, Wagenknecht LE, Raffield LM, Register TC, Carr JJ, Bowden DW, Divers J. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015 Jan; 87(1):176-81.
Score: 0.107
-
Lorenzo C, Hartnett S, Hanley AJ, Rewers MJ, Wagenknecht LE, Karter AJ, Haffner SM. Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab. 2013 Apr; 98(4):1622-30.
Score: 0.097
-
Hellwege JN, Palmer ND, Raffield LM, Ng MC, Hawkins GA, Long J, Lorenzo C, Norris JM, Ida Chen YD, Speliotes EK, Rotter JI, Langefeld CD, Wagenknecht LE, Bowden DW. Genome-wide family-based linkage analysis of exome chip variants and cardiometabolic risk. Genet Epidemiol. 2014 May; 38(4):345-52.
Score: 0.026
-
Donahue RP, Jacobs DR, Sidney S, Wagenknecht LE, Albers JJ, Hulley SB. Distribution of lipoproteins and apolipoproteins in young adults The CARDIA Study. Arteriosclerosis. 1989 Sep-Oct; 9(5):656-64.
Score: 0.019